NCT02776163 is a Phase 2 clinical trial of Nedaplatin in Salivary Gland Tumors, sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University.

What drugs are being tested in NCT02776163?

Interventions in NCT02776163: Nedaplatin, Docetaxel, Intensity-modulated radiotherapy.

What condition does NCT02776163 study?

NCT02776163 studies Salivary Gland Tumors, Head and Neck Cancer.

Is NCT02776163 still recruiting?

NCT02776163 is currently completed. Last updated 30 July 2024.

Last reviewed 2024-07-30 · How we verify

NCT02776163

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas

Completed Phase 2 Last updated 30 July 2024

What this trial tests

Phase 2 trial testing Nedaplatin in Salivary Gland Tumors in 107 participants. Completed in 31 December 2023.

Timeline

1 June 2016

Primary endpoint
31 December 2022

31 December 2023

Quick facts

Lead sponsor	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	107
Start date	1 June 2016
Primary completion	31 December 2022
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

Nedaplatin — full drug profile →
Docetaxel (Docetaxel) — full drug profile →
Intensity-modulated radiotherapy

Conditions studied

Salivary Gland Tumors — all drugs for Salivary Gland Tumors →
Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Who can join

Adults 18 to 70, any sex, with Salivary Gland Tumors or Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-randomized, phase II, open label study of postoperative current chemoradiotherapy for high-risk malignant salivary gland tumors of head and neck.The primary purpose of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy in these patients.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer.
Kang NW, Kuo YH, Wu HC, Ho CH, et al · · 2022 · cited 12× · PMID 36460788 · DOI 10.1038/s41598-022-25468-9
Patterns of care analysis for salivary gland cancer: a survey within the German Society of Radiation Oncology (DEGRO) and recommendations for daily practice.
von der Grün J, Rödel C, Semrau S, Balermpas P, et al · · 2022 · cited 8× · PMID 34427717 · DOI 10.1007/s00066-021-01833-x
Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience.
Laughlin BS, Ebrahimi S, Voss MM, Patel SH, et al · · 2023 · cited 4× · PMID 37152485 · DOI 10.1016/j.adro.2023.101204
Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis.
Dou S, Wang X, Xiao Y, Zhang L, et al · · 2025 · cited 3× · PMID 40225788 · DOI 10.1016/j.ctro.2025.100945
Long-Term Survival Outcomes of Concurrent Chemoradiotherapy for Postoperative High-Risk Salivary Gland Carcinomas.
Dou S, Wang X, Zhang L, Jiang W, et al · · 2026 · cited 1× · PMID 41878954 · DOI 10.1002/cam4.71722

Verify or expand the search:

Other trials of Nedaplatin

Trials testing the same drug.

NCT07046221 — Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery · Phase 2 · not yet recruiting
NCT07019181 — Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma · Phase 2 · not yet recruiting
NCT07284836 — Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Brea · Phase 2 · recruiting
NCT06508229 — Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC · Phase 2 · not yet recruiting
NCT06102395 — Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Adv · Phase 3 · recruiting

Other recruiting trials for Salivary Gland Tumors

Currently open trials in the same condition.

NCT07072143 — An International Study on Pediatric Patients With Rare Tumors. · recruiting
NCT05000892 — Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasm · Phase 2 · recruiting

Other Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University trials

Trials by the same sponsor.

NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
NCT07505251 — Development and Validation of the Periodontal Map Derived From IOS and CBCT Registration for Diagnosis and Treatment Pla · not yet recruiting
NCT07466810 — Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology · NA · not yet recruiting
NCT07533695 — Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis Patients · NA · not yet recruiting
NCT07490561 — The Impact of Assisted Hatching on Pregnancy Outcomes After Vitrified-Warmed Embryo Transfer in Advanced-age Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02776163 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Last refreshed: 30 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02776163.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing